Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL49195 | 1.00 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL49353 | 1.00 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL7647781 | 1.00 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL7644168 | 1.00 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL2917831 | 1.00 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL1679057 | 0.96 | EPHX1 (0.47) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL1678725 | 0.96 | EPHX1 (0.47) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL1679055 | 0.96 | EPHX1 (0.47) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL49819 | 0.96 | EPHX1 (0.44) | EPHX1HIF1AALDH1A1SIGMAR1KMT2A | |
| SCHEMBL1678970 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3689891-B1 | COBALT COMPLEX, PRODUCTION METHOD THEREFOR, AND CATALYST FOR HYDROSILYLATION REACTION | UNIV KYUSHU NAT UNIV CORP (JP) | 2023-03-01 | — | — | EP | disclosed |
| US-20200247957-A1 | COBALT COMPLEX, PRODUCTION METHOD THEREFOR, AND CATALYST FOR HYDROSILYLATION REACTION | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2020-08-06 | — | — | US | disclosed |
| EP-3689891-A1 | COBALT COMPLEX, PRODUCTION METHOD THEREFOR, AND CATALYST FOR HYDROSILYLATION REACTION | Kyushu University, National University Corporation (JP) | 2020-08-05 | — | — | EP | disclosed |
| EP-3118205-B1 | MONONUCLEAR RUTHENIUM COMPLEX AND ORGANIC SYNTHESIS REACTION USING SAME | UNIV KYUSHU NAT UNIV CORP (JP) | 2020-04-22 | — | — | EP | disclosed |
| EP-3269724-B1 | MONONUCLEAR IRON COMPLEX AND ORGANIC SYNTHESIS REACTION USING SAME | UNIV KYUSHU NAT UNIV CORP (JP) | 2020-04-22 | — | — | EP | disclosed |
| US-10363551-B2 | Mononuclear iron complex and organic synthesis reaction using same | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2019-07-30 | — | — | US | disclosed |
| US-10130634-B2 | Therapeutic agent for ophthalmic disease | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-11-20 | — | — | US | disclosed |
| EP-2963047-B1 | MONONUCLEAR IRON COMPLEX AND ORGANIC SYNTHESIS REACTION USING SAME | UNIV KYUSHU NAT UNIV CORP (JP) | 2018-11-14 | — | — | EP | disclosed |
| EP-2963046-B1 | MONONUCLEAR RUTHENIUM COMPLEX AND ORGANIC SYNTHESIS REACTION USING SAME | UNIV KYUSHU NAT UNIV CORP (JP) | 2018-10-17 | — | — | EP | disclosed |
| US-20180243732-A1 | MONONUCLEAR IRON COMPLEX AND ORGANIC SYNTHESIS REACTION USING SAME | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2018-08-30 | — | — | US | disclosed |
| WO-2007023618-A1 | HOMOPOLYMER AND COPOLYMER, AND PRODUCTION PROCESS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-03-01 | — | — | WO | disclosed |
| EP-0885237-B1 | OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS INC (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6562960-B1 | Oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-6455458-B1 | HIGH MOLECULAR WEIGHT POLYOLEFIN; GROUP 4 TRANSITION METAL COMPLEXES HAVING A BIDENTATE ANCILLARY LIGAND SYSTEM OF ONE CYCLOPENTADIENYL GROUP BOUND TO THE TRANSITION METAL AND A GROUP 15 OR GROUP 16 ATOM COVALENTLY BOUND THROUGH A BRIDGING | EXXONMOBIL CHEMICAL PATENTS INC. | 2002-09-24 | — | — | US | disclosed |
| EP-0885237-A1 | OLIGONUCLEOTIDE ANALOGUES | Novartis AG (CH) | 1998-12-23 | — | — | EP | disclosed |
| US-5677299-A | VASOPRESSIN OR OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1997-10-14 | — | — | US | disclosed |
| WO-1997032887-A1 | OLIGONUCLEOTIDE ANALOGUES | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | disclosed |
| US-5498609-A | Benzoazepinyl compounds as oxytocin and vasopressin antagonists | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1996-03-12 | — | — | US | disclosed |
| EP-0612319-A1 | BENZOHETEROCYCLIC COMPOUNDS AS OXYTOCIN AND VASOPRESSIN ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-31 | — | — | EP | disclosed |
| WO-1994004525-A1 | BENZOHETEROCYCLIC COMPOUNDS AS OXYTOCIN AND VASOPRESSIN ANTAGONISTS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180243732-A1 | MONONUCLEAR IRON COMPLEX AND ORGANIC SYNTHESIS REACTION USING SAME | TFRC, IDO1, H1-0 | EPHX1 3739/4885HIF1A 616/4885ALDH1A1 2768/4885 |
| US-20200247957-A1 | COBALT COMPLEX, PRODUCTION METHOD THEREFOR, AND CATALYST FOR HYDROSILYLATION REACTION | OR51E2, WEE2, SLC39A11 | EPHX1 3584/4885HIF1A 720/4885ALDH1A1 1421/4885 |
| US-10363551-B2 | Mononuclear iron complex and organic synthesis reaction using same | TFRC, IDO1, H1-0 | EPHX1 3739/4885HIF1A 616/4885ALDH1A1 2768/4885 |
| US-10130634-B2 | Therapeutic agent for ophthalmic disease | MITF, UACA, VEGFA | EPHX1 1625/4885HIF1A 100/4885ALDH1A1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.